Sponsor:
Pfizer
Code:
NCT07839884
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Sex: All
Age: 35 - 70+
Healthy Volunteers: Not accepted
Interventions
Tilrekimig
Brief summary:
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Study ID
NCT07839884
Start date
Oct 14, 2026
Status verified date
Nov, 2026
Completion date
Apr 21, 2034
Anticipated
Primary completion date
Apr 21, 2034
Anticipated
Eligibility Criteria
Sex: All
Age: 35 - 70+
Healthy Volunteers: Not accepted
Enrollment
1360 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Tilrekimig (PF-07275315)
Interventions
Tilrekimig
Primary outcome measure
Central contacts
Locations
Institute of HealthCare Assessment d/b/a Apex Clinical Research
Recruiting
San Diego, California, United States, 92120
Southeastern Research Center
Recruiting
Winston-Salem, North Carolina, United States, 27103
Clinical Research Associates of Central PA
Recruiting
DuBois, Pennsylvania, United States, 15801
Sponsor
Pfizer
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Pfizer on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.